Macrophage migration inhibitory factor (MIF) Inhibitor

ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC₅₀ of 7 μM.

4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF).

Iguratimod is an antirheumatic agent, acts as an inhibitor of COX-2, with an IC₅₀ of 20 μM (7.7 μg/mL), but shows no effect on COX-1. Iguratimod also inhibits macrophage migration inhibitory factor (MIF) with an IC₅₀ of 6.81 μM.

MIF098 is a macrophage migration inhibitory factor (MIF) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research.

Imalumab (BAX69) is a recombinant, human IgG1 monoclonal antibody that targets macrophage inhibitory factor (MIF). Imalumab can be used for the research of ovarian carcinoma, recurrent malignant ascites and cancer.

4-CPPC is a selective MIF-2 inhibitor with a K_i of 33 µM. 4-CPPC inhibits the COX2/PGE₂ pathway, reduces the levels of COX2 and mPGES-1, and decreases the production of PGE₂. 4-CPPC attenuates the formation of early atherosclerotic lesions in hyperlipidemic mice, and lowers the levels of circulating inflammatory cytokines and chemokines. 4-CPPC inhibits MIF-2-triggered cell migration. 4-CPPC improves hindlimb motor function in rats with contusion-induced spinal cord injury. 4-CPPC can be used in studies related to atherosclerosis and spinal cord injury.

D-DT/MIF-1-IN-1 (Compound 4h) is a non-competitive, non-covalent inhibitor of MIF-1 and D-DT, with IC₅₀ values of 2.4 μM and 4.0 μM against D-DT, and an IC₅₀ value of 9.8 μM against MIF-1. D-DT/MIF-1-IN-1 inhibits D-DT-induced phosphorylation of ERK and exerts antiproliferative activity in non-small cell lung cancer cells.

PAANIB-1 is a parthanatos associated apoptosis-inducing factor nuclease (PAAN)/macrophage migration inhibitor factor (MIF) inhibitor. PAANIB-1 exhibits neuroprotective activity. PAANIB-1 can be used for the research of Parkinson's disease.

Mitomycin A is an antitumor agent. Mitomycin A inhibits the spontaneous migration of mouse monocytes. Mitomycin A inhibits the production of MIF (Migration Inhibition Factor) by human lymphocytes. Mitomycin A can be used in the research of tumor diseases.

Carebastine is an Ebastine (HY-B0674) metabolite and H1-receptor antagonist. Carebastine inhibits VEGFR-2 and Akt phosphorylation. Carebastine exerts an anti-inflammatory effect by inhibiting MIF as well as TNF-α and IL-6 production. Carebastine shows anti-angiogenic activity

BTZO-1, a chemical probe, binds to Macrophage migration inhibitory factor (MIF) with a K_d value of 68.6 nM, and its binding requires the N-terminal Pro1. BTZO-1 can activate antioxidant response element (ARE)-mediated gene expression and suppress oxidative stress-induced cardiomyocyte apoptosis in vitro.

RDR 03785 is a covalent MIF inhibitor with an IC₅₀ of 0.36 μM.

MKA031 (compound 6y) is a non-competitive MIF inhibitor with an IC₅₀ value of 1.7 μM. MKA031 (compound 6y) interferes with MIF/AIF interaction, MIF nuclear translocation, and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced dependent cell death. MKA031 can be used in the study of chronic hepatitis C virus infection.

R110 is a potent, competitive inhibitor of macrophage migration inhibitory factor 2 (MIF2) tautomerase with an IC₅₀ of 15 μM. R110 has the potential for the research of cancer diseases.

TE-11 is a MIF tautomerase inhibitor with an IC₅₀ of 5.63 μM. TE-11 ameliorates CD-like colitis, reduces MIF-induced eosinophil and neutrophil migration, and prevents M1 polarization and associated metabolic reprogramming.

MIF2-IN-1 (compound 5d) is a potent inhibitor of MIF2 tautomerase with an IC₅₀ of 1.0 μM. MIF2-IN-1 suppresses the proliferation of non-small cell lung cancer cells by the induction of cell cycle arrest via deactivation of the MAPK pathway. MIF2-IN-1 has the potential for the research of cancer diseases.

MIF-IN-4 hydrochloride is potent macrophage migration inhibitory factor (MIF) inhibitor (pIC₅₀=5.01-6). MIF is a cytokine originally found to play a role in inhibiting macrophage migration.

MIF-IN-6 (compound 2d) is a potent macrophage migration inhibitory factor (MIF) inhibitor with an IC₅₀ of 1.4 μM and a K_i value of 0.96 μM, respectively. MIF-IN-6 attenuates MIF-induced ERK phosphorylation and inhibits proliferation of A549 cells.

BMY-25551 is a Mitomycin A (HY-130332) analogue that is 8 to 20 times more potent than Mitomycin C (HY-13316) in cytotoxicity to murine and human tumor cell lines. BMY-25551 can be utilized in cancer and hematologic depression research.

MIF-IN-1 (compound 14) is a potent macrophage migration inhibitory factor (MIF) inhibitor (pIC₅₀=6.87).